Page 18 - ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் சுற்றுச்சூழல் மாற்றம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் சுற்றுச்சூழல் மாற்றம் நிறுவனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் சுற்றுச்சூழல் மாற்றம் நிறுவனம் Today - Breaking & Trending Today

Govt. releases DRDO's COVID drug for emergency use


Updated:
Developed with DRL, it reduces oxygen-dependence in patients
Share Article
AAA
Defence Minister Rajnath Singh hands over the first batch of 2-DG anti Covid drug to the Union Health Minister Harsh Vardhan, in New Delhi on May 17, 2021. Photo: Twitter/@rajnathsingh
 
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan.
“One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for em ....

Uttar Pradesh , Andhra Pradesh , Tamil Nadu , Harsh Vardhan , Rajnath Singh , G Satheesh Reddy , Sunil Kant , Randeep Guleria , K Satish Reddy , Armed Forces Medical Services , Defence Ministry , Institute Of Nuclear Medicine , India Institute Of Medical Sciences , Development Organisation , Defence Research , Minister Rajnath Singh , Health Minister Dr Harsh , Director All India Institute , Medical Sciences , Nuclear Medicine , Allied Sciences , Drugs Controller General , West Bengal , 2 Deoxyd Glucose , 2 Dg , Dr Reddys Laboratories ,

Covaxin effectively neutralises all key emerging variants, says study published in Oxford journal | India News


HYDERABAD: Indigenous Covid-19 vaccine Covaxin has been able to neutralise all key emerging variants, including the double mutant B.1.617 and B.1.1.7, which was first identified in India and the UK, its developer Bharat Biotech said on Sunday.
A top official of the company also said that no difference in neutralisation was observed between B.1.1.7 (first isolated in the UK) and vaccine strain (D614G) that was used to develop Covaxin.
Citing a study published in peer-reviewed medical journal Clinical Infectious Diseases, Bharat Biotech joint managing director Suchitra Ella tweeted: “A modest reduction in neutralisation by a factor of 1.95 was observed against B.1.617 variant compared to the vaccine variant (D614G). Despite this reduction, neutralising titre levels with B.1.617 remain above levels expected to be protective.” ....

Andhra Pradesh , United Kingdom , Suchitra Ella , Oxford University Press , National Institute Of Virology , Indian Council Of Medical Research , Oxford University , Bharat Biotech , Clinical Infectious Diseases , Indian Council , Medical Research National Institute , Ndia News , Ndia News Today , Oday News , Google News , Reaking News , Covid 19 , ஆந்திரா பிரதேஷ் , ஒன்றுபட்டது கிஂக்டம் , சூச்சித்ர எல்லா , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் ப்ரெஸ் , தேசிய நிறுவனம் ஆஃப் வைராலஜி , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் , பாரத் பயோடெக் , மருத்துவ தொற்று நோய்கள் ,